Genmab A/S (GMAB) Reports Q3 Net sales of DARZALEX of $3.01B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
October 15, 2024 6:25 AM EDTCompany Announcement
Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)COPENHAGEN, Denmark; October 15, 2024 Genmab A/S (Nasdaq: GMAB) announced today that worldwide... More
